Anticancer Effects and Mechanisms of Action of Plumbagin: Review of Research Advances

Abstract

Plumbagin (PLB), a natural naphthoquinone constituent isolated from the roots of the medicinal plant Plumbago zeylanica L., exhibited anticancer activity against a variety of cancer cell lines including breast cancer, hepatoma, leukemia, melanoma, prostate cancer, brain tumor, tongue squamous cell carcinoma, esophageal cancer, oral squamous cell carcinoma, lung cancer, kidney adenocarcinoma, cholangiocarcinoma, gastric cancer, lymphocyte carcinoma, osteosarcoma, and canine cancer. PLB played anticancer activity via many molecular mechanisms, such as targeting apoptosis, autophagy pathway, cell cycle arrest, antiangiogenesis pathway, anti-invasion, and antimetastasis pathway. Among these signaling pathways, the key regulatory genes regulated by PLB were NF-kβ, STAT3, and AKT. PLB also acted as a potent inducer of reactive oxygen species (ROS), suppressor of cellular glutathione, and novel proteasome inhibitor, causing DNA double-strand break by oxidative DNA base damage. This review comprehensively summarizes the anticancer activity and mechanism of PLB.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Plumbagin (5-hydroxy-2-methyl-1,4-napthoquinone, PLB, Figure 1) is a naturally occurring naphthoquinone isolated from the roots of the medicinal plant Plumbago zeylanica L. As a vitamin K3 analog and a prooxidant, PLB has been reported to possess diverse biological activities, such as anti-inflammatory, anticancer, antidiabetic, antioxidant, antibacterial, antifungal, anti-atherosclerosis, and analgesic activities [1–6]. In particular, the anticancer activity and mechanism of PLB have become a research hotspot and increasing attention has been paid by scholars. Some scholars had reviewed the advances in tumor suppression and mechanism by PLB in year 2014 [7] and the cytotoxic potential and pharmaceutical relevance towards cancer therapy [8]. At present, there are few systematic reviews on its anticancer activity.

[figure omitted; refer to PDF]

In this review, we mainly report the recent advances in research on the anticancer activity of PLB and summarized the possible mechanism of PLB, which will provide theoretical references for its clinical application.

2. Antitumor Activity

2.1. Antibreast Cancer Activity

PLB showed antibreast cancer activity. PLB induced cytotoxicity in human breast cancer cells (MDA-MB-231 and MCF-7) along with cell cycle arrest, DNA damage, apoptosis, and suppression of telomere and telomerase activity [9] and induced cytoplasmic vacuolation and cell cycle G2/M arrest in MDA-MB-231 cells through inhibition of proteasome and disruption of sulfhydryl homeostasis[10]. In endocrine-resistant breast cancer cells (MCF-7/LCC2 and MCF7/LCC9), PLB inhibited their growth, invasion, and metastasis by suppressing Snail and altering the expression of other epithelial-mesenchymal transition (EMT) markers [11].

The nuclear factor kappa-B (NF-κB) was usually overexpressed in a subset of HER2-positive breast cancers, and its upregulation was related to the metastatic potential of HER2 overexpressed tumors. Kawiak et al. [12] proved that PLB inhibited the invasion of HER2-overexpressing breast cancer cells BT474 and SKBR3 by inhibiting IKKα-mediated NF-κB activation and downregulating NF-κB-regulated MMP-9 expression. In addition, PLB showed different anticancer effects on racially different triple-negative breast cancer cells by the NF-κB pathway and CCL2 release, such as MDA-MB-231 (MM-231) and MDA-MB-468 (MM-468), representing Caucasian Americans and African Americans, respectively [13].

PLB was known to generate ROS in cancer cells [14]. As a ROS inducer, PLB induced apoptosis of defective BRCA1 mutant triple-negative cells and mouse models by ROS-mediated DNA double-strand breaks (DSB) [15, 16] and also induced apoptosis of MCF-7 cells by increasing ROS production and loss of mitochondrial membrane potential. The generation of intracellular ROS could cause the induction of apoptosis via the p53-dependent pathway [17, 18].

PLB not only exerted antibreast cancer effect independently but also had synergistic effect with some other drugs, such as reversing the drug resistance of antibreast cancer drugs. One study found that the combination of PLB with zoledronic acid (ZA) could synergistically suppress human breast cancer MDA-MB-231SArfp cells in vitro [19], and the mechanism was related to the modulation of Notch-1-Bcl-2 signaling and simulation of the spatial structure of adenosine phosphate, which could competitively inhibit the phosphorylation of c-Jun N-terminal kinase/extracellular signal-regulated kinase (JNK/ERK) in MDA-MB-231[20]. PLB also demonstrated a synergistic inhibitory effect with tamoxifen on the growth of endocrine-resistant breast cancer cells [10], increased paclitaxel-induced cell death, and overcame paclitaxel resistance in MCF-7, BT474, and MDA-MB-468 cells through ERK-mediated apoptosis [21].

According to the above analysis, PLB showed antibreast cancer activity mainly through inhibiting proliferation and invasion as well as promoting apoptosis of breast cancer cells. Meanwhile, the molecular mechanisms were related to the NF-κB, p53-dependent, and JNK/ERK pathways. In addition, the synergistic effect of PLB could reverse the drug resistance of the cancer cells caused by other antibreast cancer drugs. Table 1 reports a summary of antibreast cancer activity of PLB.

Table 1

A summary of antibreast cancer activity.

Models	Biological activities	Action mechanism	Reference
MDA-MB-231	Induce apoptosis, cytoplasmic vacuolation inhibit cell migration	Cell cycle arrest, DNA damage, apoptosis, and suppression of telomere and telomerase activity; inhibition of proteasome and disruption of sulfhydryl homeostasis	[8, 9]
MCF-7	Induce apoptosis and inhibit cell migration	Cell cycle arrest, DNA damage, apoptosis, and suppression of telomere and telomerase activity; increasing of ROS production and MMP loss	[8, 16, 17]
MCF-7/LCC2 and MCF7/LCC9	Inhibit growth, invasion, and metastasis	Suppressing snail and altering the expression of other epithelial-mesenchymal transition (EMT) markers	[10]
BT474 and SKBR3	Inhibit invasion	Inhibiting IKKα-mediated NF-κB activation and downregulating NF-κB-regulated MMP-9 expression	[11]
MDA-MB-231	With zoledronic acid synergistically suppress	Modulation of Notch-1-Bcl-2 signaling and simulation of the spatial structure of adenosine phosphate	[18, 19]
MCF-7, BT474, and MDA-MB-468 cells	Increase paclitaxel-induced cell death and overcome paclitaxel resistance	Through ERK-mediated apoptosis	[20]

2.2. Antihepatoma Activity

PLB had antihepatoma carcinoma cell (HCC) activity. Angiogenesis is one of the hallmarks of cancer, and antiangiogenesis agents or small-molecule inhibitors are effective antitumor agents. PLB might be a promising antiangiogenic drug with significant antitumor activity in HCC. Wei et al. [22] demonstrated the finding that PLB restrained hepatocellular carcinoma angiogenesis (SMMC-7721 and Hep3B) by suppressing the migration and invasion of tumor-derived vascular endothelial cells, which was associated with suppressing the expression of angiogenesis pathways (PI3K-Akt, VEGF/KDR, and angiopoietins/Tie2) and angiogenic factors (VEGF, CTGF, ET-1, and bFGF). In addition, PLB also restrained hepatocellular carcinoma angiogenesis by stromal cell-derived factor (SDF-1)/CXCR4-CXCR7 axis [23].

Previous studies have found that increasing the ROS level inhibited cell proliferation and promoted cell apoptosis, which might be caused by decreasing the cell mitochondrial membrane potential [24, 25]. Zhu et al. further found that PLB could improve the resistance of hepatocellular carcinoma HepG2R cells to sorafenib by increasing the ROS level [26].

PLB inhibited the proliferation of SMMC-7721 cell line in a dose- and time-dependent manner and upregulated the expression levels of autophagy genes and related proteins (LC3, Beclin1, Atg7, and Atg5) that were associated with tumor apoptosis and autophagy in HCC cells and promoted apoptosis and autophagic death [27]. In addition, PLB could induce apoptosis of human HCC SMMC-7721 undergoing epithelial-mesenchymal transition by increasing the caspase-3 protein level and cleaving vimentin [28]. Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase, and the mTOR signaling pathway has been shown to regulate some cellular processes, including protein synthesis, cell growth, cell proliferation, cell death, and tumor angiogenesis[29, 30]. Therefore, PLB could inhibit proliferation and induce apoptosis of HCC through inhibiting the SIVA/mTOR signaling pathway [31]. According to the above analysis, PLB could inhibit proliferation and induce autophagy and apoptosis of HCC, and the mechanism was likely to be related to prestrain angiogenesis, ROS level, autophagy gene and protein expression levels, caspase-3 protein level, vimentin caspase-3, and SIVA/mTOR signaling pathway. Table 2 reports a summary of antihepatoma cancer activity of PLB.

Table 2

A summary of antihepatoma activity.

Models	Biological activities	Action mechanism	Reference
SMMC-7721 and Hep3B	Restrain hepatocellular carcinoma angiogenesis	Suppress the expression of angiogenesis pathways (PI3K-Akt, VEGF/KDR, and angiopoietins/Tie2) and angiogenic factors (VEGF, CTGF, ET-1, and bFGF); by stromal cell-derived factor (SDF-1)/CXCR4-CXCR7 axis	[21, 22]
HepG2R	Improve resistance of hepatocellular carcinoma	Increase the ROS level	[26]
SMMC-7721	Inhibit proliferation, induce apoptosis	Upregulate the expression levels of autophagy genes and related proteins (LC3, Beclin1, Atg7, and Atg5); increase the caspase-3 protein level and cleaving vimentin	[27, 28]
HepG2 and LM3	Inhibit proliferation and induce apoptosis	Inhibit the SIVA/mTOR signaling pathway	[31]

2.3. Antileukemic Activity

PLB had antileukemic activity. Mammalian thioredoxin reductase (TrxR) isoenzymes were selenocysteine-containing homologous flavin enzymes, which could catalyze NADPH to reduce oxidized thioredoxin and play a key role in regulating a variety of redox signaling pathways [32, 33]. Thus, TrxR might be a drug target for tumor therapy. Zhang et al. [34] demonstrated that PLB selectively targeted TrxR by alkylating the C-terminal redox active site Sec498 of this enzyme to suppress its physiological function, leading to accumulation of ROS, decline of GSH/GSSG ratio, depletion of cellular thiols, and collapse of the intracellular redox homeostasis and eventually promoted oxidative stress-mediated apoptosis of HL-60 cells. In addition, PLB could enhance TRAIL-induced apoptosis in Kasumi-1 cells by ROS-mediated upregulation of DR5 expression, activation of caspase-8, and inhibition of cFLIP expression [35]. PLB was also a potent inhibitor of the NF-κB signaling pathway and suppressor of T-ALL cell proliferation, because PLB induced caspase-dependent apoptosis of MOLT-4 cells and inhibited LPS-induced phosphorylation of p65, and the transcription of NF-κB target genes[36]. PLB effectively inhibited viability and proliferation of chronic lymphocytic leukemia cells (HG3 and MEC-1) through decreasing the ratio of Bcl-2/Bax. In addition, PLB promoted the accumulation of MEC-1 cells in the S phase and blocked cell cycle transition of HG3 cells from G0/G1 to S phase [37]. Based on the above analysis, PLB could inhibit proliferation and induce apoptosis of leukemic cells. The mechanism was likely to be related to targeting thioredoxin reductase, ROS-mediated upregulation of DR5 expression, activation of caspase-8, inhibition of cFLIP expression, decreasing ratio of Bcl-2/Bax, and NF-κB signaling pathway. Table 3 reports the antileukemic cancer activity of PLB.

Table 3

A summary of antileukemic activity.

Models	Biological activities	Action mechanism	Reference
HL-60	Promote oxidative stress-mediated apoptosis	Targeting thioredoxin reductase	[34]
Kasumi-1	Enhance TRAIL-induced apoptosis	ROS-mediated upregulation of DR5 expression, activation of caspase-8, and inhibition of cFLIP expression	[35]
MOLT-4	Induce apoptosis	Inhibit LPS-induced phosphorylation of p65, and the transcription of NF-κB target genes	[36]
HG3 and MEC-1	Inhibit viability and proliferation	Decrease the ratio of Bcl-2/Bax	[37]

2.4. Antimelanoma Activity

PLB reduced the proliferation and apoptosis of melanoma tumor cells and had radiosensitizing potential and synergistic inhibitory effect in melanoma tumor cells. For example, PLB caused the reduction of cell proliferation, induction of apoptosis, and disruption of mitochondrial membrane potential in BRAF-mutated (SK-MEL-28, WM35, and RPMI-7951), NRAS-mutated (SK-MEL-119), and BRAF/NRAS wild-type (Hs294T) melanoma cells by ROS-mediated disruption of mitochondrial membrane potential and inhibition of PI3K/AKT/mTOR signaling [38]. Further studies found that PLB also increased the production of ROS and inhibited melanoma cell growth and tumorigenicity by inducing endoplasmic reticulum (ER) stress signaling and DNA damage response (DDR) signaling[39].

The radiosensitizing potential of PLB inhibited the growth of B16F1 melanoma cells in vitro, and the mechanism was related to oxidative stress and DNA damage that led to enhanced mitochondria-mediated programmed cell death resulting in cell death. Moreover, it was proved that the ability of PLB to augment ionizing radiation induced tumor cell kill [40].

PLB had synergistic inhibitory effect with other antineoplastic drugs on the growth of melanoma through inhibiting multiple key pathways. The combination of PLB and celecoxib decreased melanoma cell proliferation and retarded vascular development of tumors mediated by inhibition of COX-2 and STAT3 leading to decreased levels of key cyclins key on which melanoma cells were dependent for survival[41]. Table 4 reports the antimelanoma activity.

Table 4

A summary of antimelanoma activity.

Models	Biological activities	Action mechanism	Reference
SK-MEL-28, WM35, RPMI-7951, SK-MEL-119, and Hs294T	Reduction of cell proliferation, induction of apoptosis, and disruption of mitochondrial membrane potential	ROS-mediated disruption of mitochondrial membrane potential and inhibition of PI3K/AKT/mTOR signaling	[38]
Melanoma cell	Inhibit melanoma cell growth and tumorigenicity	Induce endoplasmic reticulum (ER) stress signaling and DNA damage response (DDR) signaling	[39]
B16F1	Inhibit growth, radiosensitizing potential	Oxidative stress and DNA damage	[40]
Melanoma cell	With celecoxib decrease melanoma cell proliferation and retard vascular development of tumors mediated	Inhibit COX-2 and STAT3	[41]

2.5. Antiprostate Cancer Activity

PLB inhibited growth of prostate cancer cells and promoted apoptosis and autophagy. Hafeez et al. [42] confirmed PLB inhibited C57BL/6 wild-type mice tumor growth in intact as well as in a castrated Pten-KO mouse model possibly via inhibition of PKCe, Stat3, AKT activation, and epithelial-to-mesenchymal transition (EMT) markers (Vimentin and Slug). PLB also promoted apoptosis and autophagy of prostate cancer cells (PC-3 and DU145) via Sirt1 and PI3K/Akt/mTOR-mediated pathways with contribution from AMPK, p38 MAPK, visfatin, and ROS-associated pathways [43] and induced differential proteomic responses in PC-3 and DU145 cells by involving in cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transformation pathway [44].

In addition, PLB was proven to suppress BRCA1/2 silenced PCa tumor cells and directly target PCSLCs through the regulation of proliferation and inhibition of stem cell growth [45]. PLB improved the efficacy of androgen deprivation therapy (ADT) in prostate cancer. Abedinpour et al. [46] found PLB was effective in combination with drugs that prevented the synthesis of testosterone or its conversion to dihydrotestosterone (DHT). PLB decreased the androgen receptor (AR) levels in vitro, but not with drugs that bind to AR [47].

2.6. Antibrain Tumor Activity

Oncogenic transcription factor Forkhead Box M1 (FOXM1) induced the expression of genes involved in cell cycle progression and apoptosis. The activation of FOXM1 signaling was closely related to tumorigenesis [48, 49]. PLB, as a natural FOXM1 downregulator, inhibited proliferation, migration, and invasion of U87 and SHG-44 as well as induced the apoptosis of these cells [50, 51].

The expression of matrix metalloproteinases (MMP), especially MMP-2/-9, accelerated the degradation of ECM leading to the migration and invasion of tumor cells [52]. The PI3K/Akt signal transduction pathway also participated in the migration and invasion of different types of cells [53]. PLB downregulated MMP-2/9 expression and inhibited the PI3K/Akt signaling pathway to inhibit the migration and invasion of U87 and U251 cells [54]. In addition, PLB inhibited the viability and growth of U87 and MG cells and promoted cell cycle arrest at G2/M checkpoint by downregulating the cell cycle marker proteins CDK2 and CDK-4 and increased ROS generation that led to increased mitochondrial depolarization as well as activation of caspase-3/7. Akt/mTOR signaling was the potential target of PLB [55].

PLB induced DNA damage, cell cycle arrest, and apoptosis of brain tumor cells, such as human glioblastoma multiforme cells A172, KNS60, U251MG (KO), and medulloblastoma cells ONS76, and next suppressed the colony-forming ability. These effects were substantiated by the upregulation of E2F1, TNFRSF1A, downregulation of E2F1 genes, along with a drop in MDM2, cyclin B1, survivin, and BCL2 protein expression. PLB induced the elevated levels of the caspase-3/7 activity as well [56]. Some scholars have found that inhibition of telomerase could induce the death of human cancer cells because of the abnormal expression of telomerase in cancer cells, compared with normal somatic cells [57]. This finding was consistent with that of Khaw et al. [56] who proved that PLB inhibited telomerase in brain tumor cells and resulted in telomere shortening following chronic long-term treatment. Additionally, PLB displayed a highly cytotoxic activity on rat glioblastoma C6 cells ($\text{I}{\text{C}}_{50}=7.7\pm 0.28\mu \text{M}$) and caused cell death by necrosis, which was related to the increasing amount of intracellular ROS and significantly uncoupled mitochondrial oxidation from phosphorylation impairing ATP production in cells[58].

Previous studies have reported that PLB had the role in inhibiting NADPH oxidase 4 (NOX4) and regulating redox signaling [59] and protected cerebral infarction-reperfusion-induced neurogenic injury in rats through the repression of apoptosis and NF-κB activation [60]. Zhang et al. also found that PLB reduced the ROS production by regulating the expression of NOX4 and downregulated NF-κB signaling, which was induced by oxygen-glucose deprivation/reoxygenation (OGDR). PLB inhibited OGDR inducing the activation of NLRP3 inflammasome. Overall, PLB improved the OGDR-induced neurogenic injury by inhibiting NOX4-derived ROS-activated NLRP3 inflammasome [61]. Table 5 reports a summary of the antibrain tumor activity.

Table 5

A summary of the antibrain tumor activity.

Models	Biological activities	Action mechanism	Reference
U87 and SHG-44	Inhibit proliferation, migration, and invasion and induced apoptosis	Downregulate FOXM1	[50, 51]
U87 and U251	Inhibit migration and invasion	Downregulate MMP-2/9 expression and inhibit PI3K/Akt signaling pathway	[54]
U87 and MG	Inhibit the viability and growth, promoted cell cycle arrest	Downregulate the cell cycle marker proteins CDK2 and CDK-4 and increase ROS generation	[55]
A172, KNS60, U251MG, and ONS76	Induce DNA damage, cell cycle arrest, and apoptosis of brain tumor cells and suppressed the colony-forming ability	Upregulate E2F1 and TNFRSF1A and downregulate E2F1 genes, along with a drop in MDM2, cyclin B1, survivin, and BCL2 protein expression. Induce elevated levels of caspase-3/7 activity as well	[56]
Glioblastoma C6 cells	Display highly cytotoxic activity and cause cell death by necrosis	Increase the amount of intracellular ROS, and significantly uncouple mitochondrial oxidation from phosphorylation impairing ATP production in cells	[58]
Human SH-SY5Y cells	Attenuate oxygen-glucose deprivation/reoxygenation-induced injury	Inhibit NOX4-derived ROS-activated NLRP3 inflammasome	[61]

2.7. Antitongue Squamous Cell Carcinoma Activity

PLB had antitongue squamous cell carcinoma (TSCC) activity via p38 MAPK- and PI3K/Akt/mTOR-mediated and p53/GLUT1/MMP2 pathways.

PLB induced apoptosis and autophagy of SCC25 cells through the p38 MAPK- and PI3K/Akt/mTOR-mediated pathways with the contribution from the GSK3β and ROS-mediated pathways [62]. PLB also enhanced proliferation inhibition, apoptosis, and autophagy of PF (cisplatin+5-fluorouracil) on CAL27 cells by inhibiting the PI3K/AKT/mTOR-mediated pathway [63]. In addition, PLB also induced the apoptosis of HSC-3 and SAS cells through caspase-3/7 activation, and the mechanism was related to the generation of ROS, which elicited the loss of mitochondrial membrane potential accompanied with JNK and/or p53 activation [64].

Glucose transporter 1 (GLUT1) played an important role in tumor metastasis [65, 66]. The high expression of GLUT1 was shown in normal TSCC, and PLB inhibited TSCC growth via suppressing the PI3K/Akt/GLUT1 pathway [67]. Besides GLUT1, the high expression of matrix metalloproteinase 2 (MMP2) was shown in TSCC, and PLB inhibited the invasion and migration of TSCC via the p53/GLUT1/MMP2 pathway [68].

2.8. Antiesophageal Cancer

Downregulation of FOXM1 inhibited the growth of esophageal cancer cells [69–70]. This finding was consistent with that of Liu et al. [71] who proved that PLB inhibited the proliferation and induced apoptosis of KYSE-30, KYSE-70, and KYSE-140 ESCC in vitro and in vivo by the downregulation of FOXM1 expression. In addition, previous studies have demonstrated that the overexpression of PLK1 played an essential role in the proliferation and apoptosis resistance of ESCC cells [72, 73]. Cao et al. [74] found that PLK1 was a critical mediator of PLB-induced AKT inactivation. PLB directly downregulated the PLK1 mRNA expression by abolishing the activity of STAT3, a transcriptional factor of PLK1. Taken together, PLB inhibited the proliferation and survival against KYSE150 and KYSE450 ESCC by abrogating the STAT3-PLK1-AKT signaling.

2.9. Antioral Squamous Cell Carcinoma Activity

PLB suppressed the oral squamous cell carcinoma (OSCC) cell growth with IC₅₀ values ranging from 3.87 to 14.6 μM[64].

2.10. Antilung Cancer Activity

PLB inhibited the proliferation, invasion, and migration of lung cancer cells and induced their apoptosis. Kang et al. found PLB inhibited the rho-associated kinase (ROCK) pathway mediated by the FAK/AKT pathway and suppressed lung metastasis in osteopontin- (OPN-) treated NSCLC A549 cells [75]. PLB inhibited proteasome and disrupted sulfhydryl homeostasis inducing cytoplasmic vacuolation, cell cycle sub G1 arrest, and decreased viability in A549 cells [10].

PLB also inhibited the proliferation and induced the apoptosis of the Lewis lung carcinoma cell line in a dose-dependent manner by downregulating the expression of Bcl-2, VEGF[76], and significantly inhibited the proliferation and invasion of L9981 and NL9980 cells by targeting the IL-6/STAT3 signaling pathway[77, 78].

2.11. Antikidney Adenocarcinoma Activity

PLB inhibited proliferation and induced apoptosis of kidney adenocarcinoma 786-O cell, and the cell cycle arrested in S and G2/M phases. The mechanism was related to inducing cell membrane integrity damage, reducing mTOR, BCL2, and MDM2 protein levels, and increasing CDKN1A (p21) transcripts and yH2AX phosphorylation levels [79].

2.12. Anticholangiocarcinoma Activity

PLB potently exhibited the inhibitory effect on cholangiocarcinoma (CCA) cell line CL-6 growth ($\text{I}{\text{C}}_{50}=24.00\pm 3.33\mu \text{M}$) compared with 5-FU-treated cells ($\text{I}{\text{C}}_{50}=1036.00\pm 137.77\mu \text{M}$). PLB induced CL-6 cell apoptosis through the stimulation of caspase 3/7 activities [80].

2.13. Antigastric Cancer Activity

PLB was a potential regulator of cellular growth, migration, invasion, and apoptosis via the upregulation of SHP1 expression and inhibition of jaK2/Stat3 pathway in gastric cancer cells. PLB also inhibited Stat3 pathway through the induction of SHP1 activity in stomach cancer cells [81].

2.14. Anticervical Cancer Activity

PLB induced cytoplasmic vacuolation and cell cycle G2 to M arrest that resulted in the decreasing of cell viability in HeLa cells, which was related to the inhibition of proteasome and disruption of sulfhydryl homeostasis [10].

2.15. Antilymphocyte Carcinoma Activity

PLB induced the apoptosis in both mouse and human T-cell lymphoma cell lines via increasing the oxidative stress, caspase activity, and loss of mitochondrial membrane potential, and oxidative stress-mediated tumor cytotoxicity operates through sustained JNK activation via a novel redox-mediated regulation of MKP-1 and MKP-2[82].

2.16. Antiosteosarcoma Activity

PLB had antiosteosarcoma activity, mainly reflected by the fact that PLB could inhibit the proliferation and migration of osteosarcoma and induce apoptosis in a dose-dependent manner. The mechanism was related to the suppression of Ezrin and p-Ezrin, inhibiting VEGF and MMP-2/9 genes and proteins, increasing the intracellular ROS level and activation of the mitochondrial pathway [83–85].

2.17. Anticanine Cancer Activity

The Na⁺/K⁺-ATP enzyme (NKA) complex was not only the main regulator of membrane potential but also the target of anticancer therapy. NKA was sensitive to oxidative stress, and the expression of NKA was significantly downregulated in expressing oxidative stress cells, which could easily lead to cell death [86, 87]. PLB, as an oxidative stress-causing agent, showed anticanine cancer activity by regulating the activity of NKA. This conclusion was found by Qi et al. (2017) who proved PLB induced apoptosis of canine cancer cells via oxidative stress by inhibition of oxidative phosphorylation. Thus, it was concluded that PLB-induced oxidative stress led to the inhibition of NKA in canine cancer cells [88].

3. Conclusions and Future Perspective

PLB, as a vitamin K3 analog and a prooxidant, has been reported to possess anticancer activities on a variety of cancer cells. It showed apoptosis, autophagy, antiproliferative, anti-invasive, antimigration, antiangiogenesis property, and cell cycle arrest against various cancers by targeting multiple signaling pathways, generating excess ROS, and disrupting the function of sulfhydryl homeostasis and proteasomal.

Nowadays, due to the side effects of cancer treatment and drug resistance, cancer treatment is in urgent need of a multitarget treatment. Based on a variety of antitumor mechanisms, and combined with existing radiotherapy and chemotherapy, PLB is expected to become an anticancer drug. However, the therapeutic potential of PLB was hindered because it could not reach the tumor specifically at the therapeutic concentration after intravenous administration, and PLB had no secondary effect on normal tissue. Its use in clinic was further limited by its poor aqueous solubility, spontaneous sublimation property, and rapid elimination in vivo[89–91]. But some scholars have found that nano or metal formula could improve this disadvantage, such as PLB-silver nanoparticle [92], yttrium (III) complex of PLB [93], pH-responsive bone-targeting drug delivery system (ZA-anchored bimodal mesoporous silica covered gadolinium(III) upconversion nanoparticles loaded with PLB) [94], and transferrin-bearing liposomes entrapping PLB [91].

The review in this paper will be helpful to the research of PLB as antineoplastic drug and further development of its potential clinical application. Further study is needed to clarify the action mechanism of PLB.

Authors’ Contributions

Zhenhua Yin and Juanjuan Zhang are cofirst authors of this study.

Acknowledgments

We thank the Key Research Projects of Colleges and Universities in Henan Province (21B360006), Henan Province Industry-University-Research Cooperation Project (182107000033), the Special Fund Project of Zhengzhou Basic and Applied Basic Research (ZZSZX202003) for financial support, and every author of all the references cited herein for their valuable contributions.

References

[1] W. Zheng, Z. Tao, C. Chen, C. Zhang, H. Zhang, X. Ying, H. Chen, "Plumbagin prevents IL-1 β -induced inflammatory response in human osteoarthritis chondrocytes and prevents the progression of osteoarthritis in mice," Inflammation, vol. 40 no. 3, pp. 849-860, DOI: 10.1007/s10753-017-0530-8, 2017.

[2] Y. Shao, M. Dang, Y. Lin, F. Xue, "Evaluation of wound healing activity of plumbagin in diabetic rats," Life Sciences, vol. 231,DOI: 10.1016/j.lfs.2019.04.048, 2019.

[3] P. S. Gwee, K. S. Khoo, H. C. Ong, N. W. Sit, "Bioactivity guided isolation and structural characterization of the antifungal compound，plumbagin, from Nepenthes gracilis," Pharmaceutical Biology, vol. 52 no. 12, pp. 1526-1531, DOI: 10.3109/13880209.2014.902083, 2014.

[4] S. Kaewbumrung, P. Panichayupakaranant, "Antibacterial activity of plumbagin derivative rich Plumbago indica root extracts and chemical stabilit," Natural Product Research, vol. 28 no. 11, pp. 35-837, 2019.

[5] I. Sharma, D. Gusain, V. Dixit, "Hypolipidaemic and antiatherosclerotic effects of plumbagin in rabbits," Indian Journal of Physiology and Pharmacology, vol. 35 no. 1, pp. 10-14, 1991.

[6] P. Luo, Y. F. Wong, L. Ge, Z. F. Zhang, Y. Liu, L. Liu, H. Zhou, "Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear Factor- κ B activation," Journal of Pharmacology and Experimental Therapeutics, vol. 335 no. 3, pp. 735-742, DOI: 10.1124/jpet.110.170852, 2010.

[7] H. Qiao, T. Y. Wang, T. T. Tang, "Advances in tumor suppression by plumbagin and it mechanism," Tumori, vol. 34 no. 10, pp. 957-962, 2014.

[8] S. K. Tripathi, M. Panda, B. K. Biswal, "Emerging role of plumbagin: cytotoxic potential and pharmaceutical relevance towards cancer therapy," Food and Chemical Toxicology, vol. 125, pp. 566-582, DOI: 10.1016/j.fct.2019.01.018, 2019.

[9] S. Sameni, M. P. Hande, "Plumbagin triggers DNA damage response, telomere dysfunction and genome instability of human breast cancer cells," Biomedicine & Pharmacotherapy, vol. 82, pp. 256-268, DOI: 10.1016/j.biopha.2016.05.007, 2016.

[10] A. Binoy, D. Nedungadi, N. Katiyar, C. Bose, S. A. Shankarappa, B. G. Nair, N. Mishra, "Plumbagin induces paraptosis in cancer cells by disrupting the sulfhydryl homeostasis and proteasomal function," Chemico-Biological Interactions, vol. 310,DOI: 10.1016/j.cbi.2019.108733, 2019.

[11] N. Sakunrangsit, N. Kalpongnukul, T. Pisitkun, W. Ketchart, "Plumbagin enhances tamoxifen sensitivity and inhibits tumor invasion in endocrine resistant breast cancer through EMT regulation," Phytotherapy Research, vol. 30 no. 12, pp. 1968-1977, DOI: 10.1002/ptr.5702, 2016.

[12] A. Kawiak, A. Domachowska, "Plumbagin suppresses the invasion of HER2-overexpressing breast cancer cells through inhibition of IKK α -mediated NF- κ B activation," PLoS One, vol. 11 no. 10, article e0164064, 2016.

[13] S. S. Messeha, N. O. Zarmouh, P. Mendonca, H. Alwagdani, M. G. Kolta, K. F. A. Soliman, "The inhibitory effects of plumbagin on the NF- қ B pathway and CCL2 release in racially different triple-negative breast cancer cells," PLoS One, vol. 13 no. 7, 2018.

[14] P. Srinivas, G. Gopinath, A. Banerji, A. Dinakar, G. Srinivas, "Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells," Molecular Carcinogenesis, vol. 40 no. 4, pp. 201-211, DOI: 10.1002/mc.20031, 2004.

[15] V. Somasundaram, S. K. Hemalatha, K. Pal, S. Sinha, A. S. Nair, D. Mukhopadhyay, P. Srinivas, "Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells," BMC Cancer, vol. 16 no. 1, pp. 336-336, DOI: 10.1186/s12885-016-2372-4, 2016.

[16] R. S. Nair, J. M. Kumar, J. Jose, V. Somasundaram, S. K. Hemalatha, S. K. Sengodan, R. Nadhan, T. V. Anilkumar, P. Srinivas, "Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA double strand breaks (DSB)," Scientific Reports, vol. 6 no. 1, 2016.

[17] V. Kuete, L. K. Omosa, V. R. Sipowo Tala, J. O. Midiwo, A. T. Mbaveng, S. Swaleh, O. Karaosmanoğlu, H. Sivas, "Cytotoxicity of plumbagin, rapanone and12 other naturally occurring quinones from Kenyan Flora towards human carcinoma cells," BMC Pharmacology and Toxicology, vol. 17, 2016.

[18] U. De, J. Y. Son, Y. Jeon, S.-Y. Ha, Y. J. Park, S. Yoon, K.-T. Ha, W. S. Choi, B. M. Lee, I. S. Kim, J. H. Kwak, H. S. Kim, "Plumbagin from a tropical pitcher plant ( Nepenthes alata Blanco) induces apoptotic cell death via a p53-dependent pathway in MCF-7 human breast cancer cells," Food and Chemical Toxicology, vol. 123, pp. 492-500, DOI: 10.1016/j.fct.2018.11.040, 2019.

[19] H. Qiao, T.-y. Wang, W. Yan, A. Qin, Q.-m. Fan, X.-g. Han, Y.-g. Wang, T.-t. Tang, "Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro," Acta Pharmacologica Sinica, vol. 36 no. 9, pp. 1085-1098, DOI: 10.1038/aps.2015.42, 2015.

[20] H. Qiao, T. Wang, Z. Yu, X. Han, X. Liu, Y. Wang, Q. Fan, A. Qin, T. Tang, "Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model," Cell Death and Disease, vol. 7 no. 2, article e2094,DOI: 10.1038/cddis.2016.11, 2016.

[21] A. Kawiak, A. Domachowska, E. Lojkowska, "Plumbagin increases paclitaxel-induced cell death and overcomes paclitaxel resistance in breast cancer cells through ERK-mediated apoptosis induction," Journal of Natural Products, vol. 82 no. 4, pp. 878-885, 2019.

[22] Y. F. Wei, Q. Yang, Y. Zhang, T. J. Zhao, X. M. Liu, J. Zhong, J. Ma, Y. X. Chen, C. Zhao, J. X. Li, "Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells," Oncotarget, vol. 8 no. 9, pp. 15230-15241, DOI: 10.18632/oncotarget.14774, 2017.

[23] J. Zhong, J. Li, J. Wei, D. Huang, L. Huo, C. Zhao, Y. Lin, W. Chen, Y. Wei, "Plumbagin restrains hepatocellular carcinoma angiogenesis by stromal cell-derived factor (SDF-1)/CXCR4-CXCR7 axis," Medical Science Monitor, vol. 25, pp. 6110-6119, DOI: 10.12659/MSM.915782, 2019.

[24] A. Simao, "Carcinoma Hepatocelular: Dados Portugueses de Doentes com Hepatite B Cronica sob Terapeutica Antiviral e do Tratamento com Sorafenib," GE Portuguese Journal of Gastroenterology, vol. 23 no. 5, pp. 231-232, DOI: 10.1016/j.jpge.2016.08.001, 2016.

[25] D. Jia, W. Lu, X. Zhang, G. Cai, L. Teng, X. Wang, M. Zhang, Y. Zeng, C. Liang, D. Wang, "Calf spleen extractive injection (CSEI), a small peptides enriched extraction, induces human hepatocellular carcinoma cell apoptosis via ROS/MAPKs dependent mitochondrial pathway," Journal of Pharmacological Sciences, vol. 132 no. 2, pp. 122-130, DOI: 10.1016/j.jphs.2016.08.006, 2016.

[26] D. Q. Zhu, X. J. Chen, "Effect of plumbagin on proliferation and apoptosis of hepatocellular carcinoma HepG2R cells resistant to sorafinib and its mechanism," Journal of Jilin University (Medicine Edition), vol. 44 no. 6, pp. 1223-1229, 2018.

[27] Y. Lin, Y. Chen, S. Wang, J. Ma, Y. Peng, X. Yuan, B. Lv, W. Chen, Y. Wei, "Plumbagin induces autophagy and apoptosis of SMMC-7721 cells in vitro and in vivo," Journal of Cellular Biochemistry, vol. 120 no. 6, pp. 9820-9830, 2019.

[28] Y. Wei, B. Lv, J. Xie, Y. Zhang, Y. Lin, S. S. Wang, J. Zhong, Y. Chen, Y. Peng, J. Ma, "Plumbagin promotes human hepatoma SMMC-7721 cell apoptosis via caspase-3/vimentin signal-mediated EMT," Drug Design Development and Therapy, vol. 13, pp. 2343-2355, DOI: 10.2147/DDDT.S204787, 2019.

[29] D. M. Sabatini, H. Erdjument-Bromage, M. Lui, P. Tempst, S. H. Snyder, "RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs," Cell, vol. 78 no. 1, pp. 35-43, DOI: 10.1016/0092-8674(94)90570-3, 1994.

[30] J. Heitman, N. R. Movva, M. N. Hall, "Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast," Science, vol. 253 no. 5022, pp. 905-909, DOI: 10.1126/science.1715094, 1991.

[31] T. Li, M. Lv, X. Chen, Y. Yu, G. Zang, Z. Tang, "Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA," Drug Design Development and Therapy, vol. 13, pp. 1289-1300, DOI: 10.2147/DDDT.S200610, 2019.

[32] E. S. Arner, "Focus on mammalian thioredoxin reductases -- important selenoproteins with versatile functions," Biochimica et Biophysica Acta, vol. 1790 no. 6, pp. 495-526, DOI: 10.1016/j.bbagen.2009.01.014, 2009.

[33] A. Matsuzawa, "Thioredoxin and redox signaling: roles of the thioredoxin system in control of cell fate," Archives of Biochemistry and Biophysics, vol. 617, pp. 101-105, 2017.

[34] J. Zhang, S. Peng, X. Li, R. Liu, X. Han, J. Fang, "Targeting thioredoxin reductase by plumbagin contributes to inducing apoptosis of HL-60 cells," Archives of Biochemistry and Biophysics, vol. 619, pp. 16-26, DOI: 10.1016/j.abb.2017.02.007, 2017.

[35] X. Kong, J. Luo, T. Xu, Y. Zhou, Z. Pan, Y. Xie, L. Zhao, Y. Lu, X. Han, Z. Li, L. Liu, "Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi-1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP," Oncology Reports, vol. 37 no. 6, pp. 23-3432, 2017.

[36] K. J. Bae, Y. Lee, S. A. Kim, J. Kim, "Plumbagin exerts an immunosuppressive effect on human T-cell acute lymphoblastic leukemia MOLT-4 cells," Biochemical and Biophysical Research Communications, vol. 437 no. 1, pp. 272-277, 2016.

[37] C. Fu, Y. Gong, X. Shi, Z. Sun, M. Niu, W. Sang, L. Xu, F. Zhu, Y. Wang, K. Xu, "Plumbagin reduces chronic lymphocytic leukemia cell survival by downregulation of Bcl-2 but upregulation of the Bax protein level," Oncology Reports, vol. 36 no. 3, pp. 1605-1611, DOI: 10.3892/or.2016.4950, 2016.

[38] R. L. Pearlman, H. C. Pal, C. A. Elmets, F. Afaq, "Plumbagin induces apoptosis in melanoma cells by ROS-mediated disruption of mitochondrial membrane potential and inhibition of PI3K/AKT/mTOR signaling," Journal of Investigative Dermatology, vol. 136 no. 5, 2016.

[39] F. Afaq, P. Sharma, S. F. McClees, R. L. Pearlman, H. C. Pal, "817 Plumbagin inhibits melanoma cell growth and tumorigenicity by inducing ER Stress and DDR signaling," Journal of Investigative Dermatology, vol. 137 no. 5,DOI: 10.1016/j.jid.2017.02.842, 2017.

[40] B. S. S. Rao, M. R. S. Kumar, S. Das, K. Aithal, N. Udupa, "Radiosensitizing potential of Plumbagin in B16F1 melanoma tumor cells through mitochondrial mediated programmed cell death," Journal of Applied Biomedicine, vol. 13 no. 4, pp. 336-336, 2015.

[41] R. Gowda, A. Sharma, G. R. Robertso, "Synergistic inhibitory effects of celecoxib and plumbagin on melanoma tumor growth," Cancer Letter, vol. 385, pp. 243-250, 2017.

[42] B. B. Hafeez, J. W. Fischer, A. Singh, W. Zhong, A. Mustafa, L. Meske, M. O. Sheikhani, A. K. Verma, "Plumbagin inhibits prostate carcinogenesis in intact and castrated PTEN knockout mice via targeting PKC , Stat3, and epithelial-to-mesenchymal transition markers," Cancer Prevention Research, vol. 8 no. 5, pp. 375-386, DOI: 10.1158/1940-6207.CAPR-14-0231, 2015.

[43] S.-F. Zhou, Z.-W. Zhou, X.-X. Li, Z. He, S. Pan, Y.-X. Yang, X. Zhang, K. Chew, T. Yang, J. Qiu, Q. Zhou, J. Tan, D. Wang, "Induction of apoptosis and autophagy via sirtuin1-and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells," Drug Design Development and Therapy, vol. 9, pp. 1511-1554, 2015.

[44] S.-F. Zhou, J.-X. Qiu, Z.-W. Zhou, Z.-X. He, X. Zhang, L. Yang, Z.-F. Mao, R. J. Zhao, "Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells," Drug Design Development and Therapy, vol. 9, pp. 349-417, 2015.

[45] R. S. Reshma, K. H. Sreelatha, V. Somasundaram, S. Satheesh Kumar, R. Nadhan, R. S. Nair, P. Srinivas, "Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells," Pharmacological Research, vol. 105, pp. 134-145, DOI: 10.1016/j.phrs.2016.01.012, 2016.

[46] P. Abedinpour, V. T. Baron, A. Chrastina, G. Rondeau, J. Pelayo, J. Welsh, P. Borgström, "Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: a pre-clinical study," The Prostate, vol. 77 no. 16, pp. 1550-1562, DOI: 10.1002/pros.23428, 2017.

[47] G. Rondeau, P. Abedinpour, A. Chrastina, J. Pelayo, P. Borgstrom, J. Welsh, "Differential gene expression induced by anti-cancer agent plumbagin is mediated by androgen receptor in prostate cancer cells," Science Report, vol. 8 no. 1,DOI: 10.1038/s41598-018-20451-9, 2018.

[48] J. Laoukili, M. R. H. Kooistra, A. Brás, J. Kauw, R. M. Kerkhoven, A. Morrison, H. Clevers, R. H. Medema, "FoxM1 is required for execution of the mitotic programme and chromosome stability," Nature Cell Biology, vol. 7 no. 2, pp. 126-136, 2015.

[49] X. Chen, G. A. Muller, M. Quaas, M. Fischer, N. Han, B. Stutchbury, A. D. Sharrocks, K. Engeland, "The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism," Molecular and Cellular Biology, vol. 33 no. 2, pp. 227-236, 2012.

[50] X. Liu, W. Cai, M. Niu, Y. Chong, H. Liu, W. Hu, D. Wang, S. Gao, Q. Shi, J. Hu, X. Zhou, R. Yu, "Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1," Journal of Neuro-oncology, vol. 121 no. 3, pp. 469-477, DOI: 10.1007/s11060-014-1664-2, 2015.

[51] M. Niu, W. Cai, H. Liu, Y. Chong, W. Hu, S. Gao, Q. Shi, X. Zhou, X. Liu, R. Yu, "Plumbagin inhibits growth of gliomas _in vivo_ via suppression of FOXM1 expression," Journal of Pharmacological Sciences, vol. 128 no. 3, pp. 131-136, DOI: 10.1016/j.jphs.2015.06.005, 2015.

[52] S.-S. Shin, S.-S. Park, B. Hwang, B. Moon, W. T. Kim, W.-J. Kim, S.-K. Moon, "MicroRNA-892b influences proliferation, migration and invasion of bladder cancer cells by mediating the p19ARF/cyclin D1/CDK6 and Sp-1/MMP-9 pathways," Oncology Reports, vol. 36 no. 4, pp. 2313-2320, DOI: 10.3892/or.2016.5052, 2016.

[53] R. Martín-Orozco, C. Almaraz-Pro, F. J. Rodríguez-Ubreva, M. A. Cortés, S. Ropero, R. Colomer, P. López-Ruiz, B. Colás, "EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of P13K/Akt," Neoplasia, vol. 9 no. 8, pp. 614-624, DOI: 10.1593/neo.07337, 2007.

[54] G. Chen, Y. Yue, J. Qin, X. Xiao, Q. Ren, B. Xiao, "Plumbagin suppresses the migration and invasion of glioma cells via downregulation of MMP-2/9 expression and inaction of PI3K/Akt signaling pathway _in vitro_," Journal of Pharmacological Sciences, vol. 134 no. 1, pp. 59-67, DOI: 10.1016/j.jphs.2017.04.003, 2017.

[55] U. Kapoor, N. Lenka, "Plumbagin: putative mechanisms of action mediating cells cycle, metabolism, and apoptosisin glioblastoma cells," Free Radical Biology and Medicine, vol. 112, 2017.

[56] A. K. Khaw, S. Sameni, S. Venkatesan, G. Kalthur, M. P. Hande, "Plumbagin alters telomere dynamics, induces DNA damage and cell death in human brain tumour cells," Mutation Research-genetic Toxicology and Environmental Mutagenesis, vol. 793, pp. 86-95, DOI: 10.1016/j.mrgentox.2015.06.004, 2015.

[57] A. K. Khaw, M. P. Hande, G. Kalthur, "Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells," Journal of Cellular Biochemistry, vol. 114 no. 6, pp. 1257-1270, 2013.

[58] D. Majiene, J. Kuseliauskyte, A. Stimbirys, A. Jekabsone, "Comparison of the effect of native 1,4-naphthoquinones plumbagin, menadione, and lawsone on viability, redox status, and mitochondrial functions of c6 glioblastoma cells," Nutrients, vol. 11 no. 6,DOI: 10.3390/nu11061294, 2019.

[59] R. Checker, R. S. Patwardhan, D. Sharma, J. Menon, M. Thoh, S. K. Sandur, K. B. Sainis, T. B. Poduval, "Plumbagin, a vitamin K3 analogue, abrogates lipopolysaccharide-induced oxidative stress, inflammation and endotoxic shock via NF- κ B suppression," Inflammation, vol. 37 no. 2, pp. 542-554, DOI: 10.1007/s10753-013-9768-y, 2014.

[60] X. J. Chen, J. G. Zhang, L. Wu, "Plumbagin inhibits neuronal apoptosis, intimal hyperplasia and also suppresses TNF- α /NF- κ B pathway induced inflammation and matrix metalloproteinase-2/9 expression in rat cerebral ischemia," Saudi Journal of Biological Sciences, vol. 25 no. 6, pp. 1033-1039, DOI: 10.1016/j.sjbs.2017.03.006, 2018.

[61] Q. Zhang, S. Zhao, W. Zheng, H. Fu, T. Wu, F. Hu, "Plumbagin attenuated oxygen-glucose deprivation/reoxygenation-induced injury in human SH-SY5Y cells by inhibiting NOX4-derived ROS-activated NLRP3 inflammasome," Bioscience, Biotechnology, and Biochemistry, vol. 84 no. 1, pp. 134-142, DOI: 10.1080/09168451.2019.1664893, 2020.

[62] S.-F. Zhou, S.-T. Pan, Y. Qin, Z.-W. Zhou, Z. He, X. Zhang, T. Yang, Y.-X. Yang, D. Wang, J. Qiu, "Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAP-and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells," Drug Design Development and Therapy, vol. 9, pp. 1601-1626, 2015.

[63] F. Zhou, S. T. Pan, J. X. Qiu, "Plumbagin enhances the inhibition effects of PF chemotherapy regimen on tongue squamous cell carcinoma cells via PI3K/AKT/mTOR-mediated pathway," Journal of Practical Stomatology, vol. 34 no. 4, pp. 512-517, 2018.

[64] T. Ono, A. Ota, K. Ito, T. Nakaoka, S. Karnan, H. Konishi, A. Furuhashi, T. Hayashi, Y. Yamada, Y. Hosokawa, Y. Kazaoka, "Plumbagin suppresses tumor cell growth in oral squamouscell carcinoma cell lines," Oral Diseases, vol. 21 no. 4, pp. 501-511, 2015.

[65] S. Oh, H. Kim, K. Nam, I. Shin, "Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells," Journal of Biochemistry and Molecular Biology, vol. 50 no. 3, pp. 132-137, 2017.

[66] A. Koch, S. A. Lang, P. J. Wild, S. Gantner, A. Mahli, G. Spanier, M. Berneburg, M. Müller, A. K. Bosserhoff, C. Hellerbrand, "Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells," Oncotarget, vol. 6 no. 32, pp. 32748-32760, DOI: 10.18632/oncotarget.4977, 2015.

[67] S. Na, J. Zhang, X. Zhou, A. Tang, D. Huang, Q. Xu, D. Xue, J. Qiu, "Plumbagin-mediating GLUT1 suppresses the growth of human tongue squamous cell carcinoma," Oral Diseases, vol. 24 no. 6, pp. 920-929, DOI: 10.1111/odi.12799, 2018.

[68] X. M. Zhou, S. Na, S. Pan, J. Qiu, "Effect of plumbagin on invasion and migration of tongue squamous cell carcinoma cells and its mechanism," Journal Oral Science Research, vol. 34 no. 1, pp. 39-43, 2018.

[69] M. Liu, B. Dai, S.-H. Kang, K. Ban, F.-J. Huang, F. F. Lang, K. D. Aldape, T.-x. Xie, C. E. Pelloski, K. Xie, R. Sawaya, S. Huang, "FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells," Cancer Research, vol. 66 no. 7, pp. 3593-3602, DOI: 10.1158/0008-5472.CAN-05-2912, 2006.

[70] A. Takata, S. Takiguchi, K. Okada, T. Takahashi, Y. Kurokawa, M. Yamasaki, H. Miyata, K. Nakajima, M. Mori, Y. Doki, "Clinicopathological and prognostic significance of FOXM1 expression in esophageal squamous cell carcinoma," Anticancer Research., vol. 34 no. 5, pp. 2427-2432, 2014.

[71] Z. D. Liu, Z. W. Zhao, Y. J. Chen, "Plumbagin influences the proliferation and apoptosis of esophageal squamous carcinoma cell lines by down-regulation of FoxM1 expression," Acta Pharmaceutica Sinica, vol. 52 no. 4, pp. 563-568, 2017.

[72] Y. Zhang, X.-L. Du, C.-J. Wang, D.-C. Lin, X. Ruan, Y.-B. Feng, Y.-Q. Huo, H. Peng, J.-L. Cui, T.-T. Zhang, Y.-Q. Wang, H. Zhang, Q.-M. Zhan, M.-R. Wang, "Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells," Gastroenterology, vol. 142 no. 3, pp. 521-530.e3, DOI: 10.1053/j.gastro.2011.11.023, 2012.

[73] Y.-B. Feng, D.-C. Lin, Z.-Z. Shi, X.-C. Wang, X.-M. Shen, Y. Zhang, X.-L. Du, M.-L. Luo, X. Xu, Y.-L. Han, Y. Cai, Z.-Q. Zhang, Q.-M. Zhan, M.-R. Wang, "Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma," International Journal of Cancer, vol. 124 no. 3, pp. 578-588, 2009.

[74] Y.-Y. Cao, J. Yu, T.-T. Liu, K.-X. Yang, L.-Y. Yang, Q. Chen, F. Shi, J.-J. Hao, Y. Cai, M.-R. Wang, W.-H. Lu, Y. Zhang, "Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling," Cell Death and Disease, vol. 9 no. 2, 2018.

[75] C. G. Kang, E. Im, H.-J. Lee, E.-O. Lee, "Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice," Bioorganic & Medicinal Chemistry Letters, vol. 27 no. 9, pp. 1914-1918, 2017.

[76] F. Liu, J. Xie, F. Li, X. Guo, "Anticancer effect and mechanism of plumbagin on Lewis lung carcinoma in vitro and in vivo," Chinese Palharmaceutic Journal, vol. 52 no. 7, pp. 581-586, 2017.

[77] J. L. Geiger, J. R. Grandis, J. E. Bauman, "The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations," Oral Oncology, vol. 56, pp. 84-92, 2016.

[78] T. Yu, Y.-Y. Xu, Y.-Y. Zhang, K.-Y. Li, Y. Shao, G. Liu, "Plumbagin suppresses the human large cell lung cancer cell lines by inhibiting IL-6/STAT3 signaling i n vitro," International Immunopharmacology, vol. 55, pp. 290-296, 2018.

[79] I. A. Mancilla, G. C. Coatti, B. I. Biazi, T. A. Zanetti, A. Baranoski, L. A. Marques, A. C. Corveloni, S. R. Lepri, M. S. Mantovani, "Molecular pathways related to the control of proliferation and cell death in 786-O cells treated with plumbagin," Molecular Biology Reports, vol. 46 no. 6, pp. 6071-6078, 2019.

[80] L. Panrit, T. Plengsuriyakarn, P. Martviset, K. Na-Bangchang, "Inhibitory activities of plumbagin on cell migration and invasion and inducing activity on cholangiocarcinoma cell apoptosis," Asian Pacific Journal of Tropical Medicine, vol. 11 no. 7, 2018.

[81] M. K. Joo, J.-J. Park, S. H. Kim, H. S. Yoo, B. J. Lee, H. J. Chun, S. W. Lee, Y.-T. Bak, "Antitumorigenic effect of plumbagin by induction of SH2-containing protein tyrosine phosphata s e 1 in human gastric cancer cells," International Journal of Oncology, vol. 46 no. 6, pp. 2380-2388, 2015.

[82] R. Checker, L. Gambhir, D. Sharma, M. Kumar, S. K. Sandur, "Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2)," Cancer Letters, vol. 357 no. 1, pp. 265-278, 2015.

[83] L. Tian, X. Liu, Z. Guo, H. Wang, T. Zhang, "Effects of plumbagin on invasion in osteosarcoma cell line MG 63 and its possible mechanisms," Chinese Journal of Oncology Prevention and Treatment, vol. 8 no. 3, pp. 137-140, 2016.

[84] L. Tian, X. Liu, Z. Guo, H. Wang, T. Zhang, "Inhibitory effect of plumbagin on invasion and expression of matrix metalloproteinases in osteosarcoma cells in vitro," Guangdong Medical Journal, vol. 37 no. 19, pp. 2872-2875, 2016.

[85] L. Q. Tian, X. T. Liu, H. W. Wang, Z. Guo, T. Zhang, "Effect of plumbagin on proliferation and apoptosis of osteosarcoma cells and its mechanism. Plumbagin," Shandong Medical Journal, vol. 57 no. 12, pp. 42-44, 2017.

[86] A. P. Comellas, L. A. Dada, E. Lecuona, L. M. Pesce, N. S. Chandel, N. Quesada, G. R. S. Budinger, G. J. Strous, A. Ciechanover, J. I. Sznajder, "Hypoxia-mediated degradation of Na,K-ATPase via mitochondrial reactive oxygen species and the ubiquitinconjugating system," Circulation Research, vol. 98 no. 10, pp. 1314-1322, 2006.

[87] G. A. Gusarova, L. A. Dada, A. M. Kelly, C. Brodie, L. A. Witters, N. S. Chandel, J. I. Sznajder, "Alpha1-AMP-activated protein kinase regulates hypoxia-induced Na,K- ATPase endocytosis via direct phosphorylation of protein kinase C zeta," Molecular & Cellular Biology, vol. 29 no. 13, pp. 3455-3464, 2009.

[88] Y. Alharbi, A. Kapur, M. Felder, L. Barroilhet, T. Stein, B. R. Pattnaik, M. S. Patankar, "Plumbagin-induced oxidative stress leads to inhibition of Na + /K + -ATPase (NKA) in canine cancer cells," Scientific Reports, vol. 9 no. 1, 2019.

[89] A. Pawar, R. Patel, S. Arulmozhi, C. Bothiraja, "D- α -Tocopheryl polyethylene glycol 1000 succinate conjugated folic acid nanomicelles: towards enhanced bioavailability, stability, safety, prolonged drug release and synergized anticancer effect of plumbagin," RSC Advances, vol. 6, pp. 78106-78121, 2016.

[90] Y. J. Hsieh, L. C. Lin, T. H. Tsai, "Measurement and pharmacokinetic study of plumbagin in a conscious freely moving rat using liquid chromatography/tandem mass spectrometry," Journal of Chromatography B, vol. 844 no. 1, 2006.

[91] I. Sakpakdeejaroen, S. Somani, P. Laskar, M. Mullin, C. Dufès, "Transferrin-bearing liposomes entrapping plumbagin for targeted cancer therapy," Journal of Interdisciplinary Nanomedicine, vol. 4 no. 2, pp. 54-71, 2019.

[92] P. Appadurai, K. Rathinasamy, "Plumbagin-silver nanoparticle formulations enhance the cellular uptake of plumbagin and its antiproliferative activities," Iet Nanobiotechnology, vol. 9 no. 5, pp. 264-272, 2015.

[93] W. Y. Shen, Y. Q. Gu, M. X. Tan, "Studies on synthesis, structure, antitumour activity and the interaction with bovine serum albumin of Y (III) complex of plumbagin," Journal of Yulin Normal University (Natural. Science), vol. 38 no. 2, pp. 42-47, 2017.

[94] H. Qiao, Z. W. Cui, S. B. Yang, "Targeting osteocytes to attenuate early breast cancer bone metastasis by theranostic upconversion nanoparticles with responsive plumbagin release," ACS Nano, vol. 11 no. 4, pp. 4857-4857, 2017.